Raman characterization of transplant tissue
A system and method for determining a disease state and clinical outcome of a sample. A sample is illuminated to produce Raman scattered photons, the Raman scattered photons are assessed to generate a Raman spectroscopic data set representative of the sample, wherein said Raman spectroscopic data set comprises at least one of: a Raman spectra of the sample and a spatially accurate wavelength resolved Raman image of the sample; the Raman spectroscopic data set is evaluated using a chemometric technique to classify the disease state of the sample as: acute, chronic, incipient, or none. In one embodiment, the chemontric technique is principle component analysis. In another embodiment, the sample is obtained prior to transplantation and analysis can determine the likelihood of rejection by a host.
1. A method comprising:
selecting a pre-determined vector space that mathematically describes a First plurality of reference spectral data sets representative of a biological tissue in a state of rejection and a second plurality of reference spectral data sets representative of a biological tissue not in a state of rejection;
irradiating a sample to thereby produce Raman scattered photons, wherein said sample comprises a biological tissue;
collecting said photons to thereby generate a test spectral data set representative of said sample;
transforming the test spectral data set into said pre-determined vector space;
analyzing a distribution of transformed data in the pre-determined vector space;
and based on said analysis, classifying the sample as at least one of: a biological tissue in no state of rejection, a biological tissue in a state of acute rejection, a biological tissue in a state of chronic rejection, and a biological tissue in a state of incipient rejection.
2. The method of claim 1 wherein said biological tissue comprises tissue associated with at least one of: kidney, heart, pancreas, prostate, lung, liver, blood, muscle, bladder, intestine, stomach, cornea, lens, bone, and skin.
3. The method of claim 1 further comprising determining a clinical outcome of a patient associated with said sample.
4. The method of claim 3 wherein said clinical outcome comprises at least one of: organ failure and organ function.
5. The method of claim 1 wherein said sample is obtained by a method selected from the group consisting of: fine needle aspiration, core biopsy, surgical biopsy, and combinations thereof.
6. The method of claim 1 wherein said first plurality of reference spectral data sets is further representative of a disease state that is selected from the group consisting of: a state of acute rejection, a state of chronic rejection, and a state of incipient rejection.
7. The method of claim 1 wherein said second plurality of reference spectral data sets is further representative of no disease state.
8. The method of claim 1 wherein said first plurality of reference spectral data sets comprises at least one of a plurality of reference Raman spectra and a plurality of reference spatially accurate wavelength resolved Raman images.
9. The method of claim 1 wherein said second plurality of reference spectral data sets comprises at least one of: a plurality of reference Raman spectra and a plurality of reference spatially accurate wavelength resolved Raman images.
10. A method comprising:
selecting a pre-determined vector space that mathematically describes a first plurality of reference spectral data sets representative of a biological tissue in a state of rejection and a second plurality of reference spectral data sets representative of a biological tissue not in a state of rejection;
irradiating a sample to thereby produce Raman scattered photons, wherein said sample comprises a biological tissue obtained before transplantation into a host;
collecting said photons to. thereby generate a test spectral data set representative of said sample;
transforming the test spectral data set into said pre-determined vector space;
analyzing a distribution of transformed data in the pre-determined vector space;
and based on said analysis, classifying the sample as at least one of: a biological tissue that will be rejected by a host and a biological tissue that will not be rejected by a host.
11. The method of claim 10 wherein said biological tissue, comprises tissue associated with at least one of: kidney, heart, pancreas, prostate, lung, liver, blood, muscle, bladder, intestine, stomach, cornea, lens, bone, and skin.
12. The method of claim 10 further comprising determining a clinical outcome of a patient associated with said sample.
13. The method of claim 12 wherein said clinical outcome comprises at least one of: organ failure and organ function.
14. The method of claim 10 wherein said sample is obtained by a method selected from the group consisting of: fine needle aspiration, core biopsy, surgical biopsy, and combinations thereof.
15. The method of claim 10 wherein said first plurality of reference spectral data sets is further representative of a disease state that is selected from the group consisting of: a state of acute rejection, a state of chronic rejection, and a state of incipient rejection.
16. The method of claim 10 wherein said second plurality of reference spectral data sets is further representative of no disease state.
17. The method of claim 10 wherein said first plurality of reference spectral data sets comprises at least one of: a plurality of reference Raman spectra and a plurality of reference spatially accurate wavelength resolved Raman images.
18. The method of claim 10 wherein said second plurality of reference spectral data sets comprises at least one of: a plurality of reference Raman spectra and a plurality of reference spatially accurate wavelength resolved Raman images.